Algonquin Power (AQN) stays a 2026E BUY as it shifts to regulated utility, cuts debt, and targets 20% earnings growth—read the outlook and size wisely.
Pharming Group has transitioned from a speculative play to a fundamentally attractive, cash-generating rare disease company.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results